After a Ph.D in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I.
She then joined Sanofi Diagnostics Pasteur, at Chaska MN (USA) for 3 years where she was responsible for Assay Development in the immunodiagnostic area. She completed an Executive MBA in 2003 and had worked for 7 years as a Director of Business Unit at Bio- Rad. After installing the biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg). Since Jan 2016, she is now the CEO of Luxembourg Institute of Health.
She is an author of 87 publications and filed 13 patents. Her main expertise relies on cardiometabolic biomedical research as well as on personalised medicine as she participated in a series of workshops leading to a “white paper” in June 2015.
She served in standardisation committees at AACC and IFCC for 15 years; she also created and chaired the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She is currently serving as an expert for the European Commission (H2020 and IMI programmes).